Palisade Bio (PALI) Research & Development (2010 - 2026)
Palisade Bio (PALI) reported Research & Development of $6.0 million for Q1 2026, up 531.58% year-over-year from $950000.0 in Q1 2025, and down 2.8% on a QoQ basis from $6.2 million in Q4 2025.
Palisade Bio (PALI) has 17 years of Research & Development data on file, last reported at $6.0 million in Q1 2026.
- Quarterly Research & Development rose 531.58% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.2 million (down 29.64% YoY) and the FY2025 annual result came in at $10.2 million, up 12.46% from the prior year.
- Research & Development fell to $6.0 million in Q1 2026 per PALI's latest filing, from $6.2 million in the prior quarter.
- Across five years, Research & Development topped out at $16.0 million in Q3 2024 and bottomed at $362000.0 in Q4 2023.
- The 5-year median for Research & Development is $2.1 million (2024), against an average of $3.0 million.
- The widest annual swing landed in 2024, when Research & Development jumped 660.46%; it then slumped 91.29% in 2025.
- Tracing PALI's Research & Development over 5 years: stood at $2.3 million in 2022, then tumbled by 84.55% to $362000.0 in 2023, then soared by 475.69% to $2.1 million in 2024, then surged by 196.21% to $6.2 million in 2025, then retreated by 2.8% to $6.0 million in 2026.
- Per Business Quant, the three latest PALI Research & Development figures stand at $6.0 million (Q1 2026), $6.2 million (Q4 2025), and $1.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 6.17 Mn |
| Sep 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 950,000.00 |
| Dec 31, 2024 | 2.08 Mn |
| Sep 30, 2024 | 16.00 Mn |
| Jun 30, 2024 | 2.63 Mn |
| Mar 31, 2024 | 2.21 Mn |
| Dec 31, 2023 | 362,000.00 |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 2.18 Mn |
| Mar 31, 2023 | 1.24 Mn |
| Dec 31, 2022 | 2.34 Mn |
| Sep 30, 2022 | 1.93 Mn |
| Jun 30, 2022 | 1.32 Mn |
| Mar 31, 2022 | 959,000.00 |
| Dec 31, 2021 | 800,000.00 |
| Sep 30, 2021 | 624,000.00 |
| Jun 30, 2021 | 314,000.00 |
| Mar 31, 2021 | 692,000.00 |
| Dec 31, 2020 | 785,000.00 |
| Sep 30, 2020 | 412,000.00 |
| Jun 30, 2020 | 650,000.00 |
| Mar 31, 2020 | 696,889.00 |
| Dec 31, 2019 | 767,048.00 |
| Sep 30, 2019 | 825,486.00 |
| Jun 30, 2019 | 954,453.00 |
| Mar 31, 2019 | 1.51 Mn |
| Dec 31, 2018 | 878,872.00 |
| Sep 30, 2018 | 897,098.00 |
| Jun 30, 2018 | 1.01 Mn |
| Mar 31, 2018 | 1.17 Mn |
| Dec 31, 2017 | 1.23 Mn |
| Sep 30, 2017 | 1.38 Mn |
| Jun 30, 2017 | 2.59 Mn |
| Mar 31, 2017 | 2.90 Mn |
| Dec 31, 2016 | 4.03 Mn |
| Sep 30, 2016 | 3.59 Mn |
| Jun 30, 2016 | 2.47 Mn |
| Mar 31, 2016 | 3.07 Mn |
| Dec 31, 2015 | 2.75 Mn |
| Sep 30, 2015 | 3.39 Mn |
| Jun 30, 2015 | 3.31 Mn |
| Mar 31, 2015 | 3.18 Mn |
| Dec 31, 2014 | 2.61 Mn |
| Sep 30, 2014 | 2.11 Mn |
| Jun 30, 2014 | 2.00 Mn |
| Mar 31, 2014 | 1.63 Mn |
| Dec 31, 2013 | 1.78 Mn |
| Sep 30, 2013 | 1.85 Mn |
| Jun 30, 2013 | 1.91 Mn |
| Mar 31, 2013 | 1.75 Mn |
| Dec 31, 2012 | 1.70 Mn |
| Sep 30, 2012 | 1.39 Mn |
| Jun 30, 2012 | 1.60 Mn |
| Mar 31, 2012 | 1.42 Mn |
| Dec 31, 2011 | 1.41 Mn |
| Sep 30, 2011 | 2.12 Mn |
| Jun 30, 2011 | 2.09 Mn |
| Mar 31, 2011 | 1.74 Mn |
| Dec 31, 2010 | 2.54 Mn |
| Sep 30, 2010 | 2.11 Mn |
| Jun 30, 2010 | 2.61 Mn |